Peter R Dixon1, Michael Au1, Ali Hosni, Bayardo Perez-Ordonez2, Ilan Weinreb2, Wei Xu3, Yuyao Song3, Shao Hui Huang4, Brian O'Sullivan4, David P Goldstein1, John R de Almeida1. 1. Department of Otolaryngology - Head and Neck Surgery, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada. 2. Department of Pathology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada. 3. Department of Biostatistics, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada. 4. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Abstract
BACKGROUND: The prognostic significance of human papillomavirus (HPV) in the context of head and neck squamous cell carcinoma (HNSCC) of cancer of unknown primary (CUP) origin is unclear. METHODS: Patients treated for CUP at the Princess Margaret Cancer Centre between 2001 and 2013 were stratified by p16 status and retrospectively reviewed. RESULTS: Of the 73 patients included, those with p16-positive tumors (63%) had less advanced nodal status (N1-N2b; 52% vs 89%; p = .035) and less aggressive treatment. Patients with p16-positive tumors had improved 3-year disease-free survival (DFS; 79% vs 56%; p = .012) independent of nodal status and treatment in multivariable analysis (hazard ratio [HR] = 0.27; 95% confidence interval [CI] = 0.08-0.95). CONCLUSION: Among patients with CUP, p16-positive status is an independent predictor of DFS but not overall survival (OS).
BACKGROUND: The prognostic significance of human papillomavirus (HPV) in the context of head and neck squamous cell carcinoma (HNSCC) of cancer of unknown primary (CUP) origin is unclear. METHODS:Patients treated for CUP at the Princess Margaret Cancer Centre between 2001 and 2013 were stratified by p16 status and retrospectively reviewed. RESULTS: Of the 73 patients included, those with p16-positive tumors (63%) had less advanced nodal status (N1-N2b; 52% vs 89%; p = .035) and less aggressive treatment. Patients with p16-positive tumors had improved 3-year disease-free survival (DFS; 79% vs 56%; p = .012) independent of nodal status and treatment in multivariable analysis (hazard ratio [HR] = 0.27; 95% confidence interval [CI] = 0.08-0.95). CONCLUSION: Among patients with CUP, p16-positive status is an independent predictor of DFS but not overall survival (OS).
Authors: Won Ki Cho; Jong-Lyel Roh; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim Journal: J Cancer Res Clin Oncol Date: 2019-12-19 Impact factor: 4.553
Authors: Diako Berzenji; Dominiek A Monserez; Gerda M Verduijn; Emilie A C Dronkers; Peter P Jansen; Stijn Keereweer; Aniel Sewnaik; Robert J Baatenburg de Jong; Jose A Hardillo Journal: Laryngoscope Investig Otolaryngol Date: 2021-03-26
Authors: Francisco J Civantos; Jan B Vermorken; Jatin P Shah; Alessandra Rinaldo; Carlos Suárez; Luiz P Kowalski; Juan P Rodrigo; Kerry Olsen; Primoz Strojan; Antti A Mäkitie; Robert P Takes; Remco de Bree; June Corry; Vinidh Paleri; Ashok R Shaha; Dana M Hartl; William Mendenhall; Cesare Piazza; Michael Hinni; K Thomas Robbins; Ng Wai Tong; Alvaro Sanabria; Andres Coca-Pelaz; Johannes A Langendijk; Juan Hernandez-Prera; Alfio Ferlito Journal: Front Oncol Date: 2020-11-10 Impact factor: 6.244